12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TRU-016: Phase Ib started

Emergent began an open-label, U.S. Phase Ib trial to evaluate IV TRU-016 given weekly for 8 weeks followed by 4 monthly doses plus rituximab in about 24 previously untreated patients. Patients will receive 10 mg/kg TRU-016 for the first dose and 20 mg/kg thereafter. TRU-016 is in Phase II testing to...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >